Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 31, 2012
Singapore (January 31, 2012) – Boston Scientific Corporation (NYSE: BSX) announces the creation of its Asia-Pacific regional organization that includes Australia, New Zealand, China, Hong Kong,...
-
Jan 26, 2012NICE Report Supports Safety and Effectiveness of Alair® System
London (January 26, 2012) -- Boston Scientific (UK) welcomes new guidance from the National Institute for Health and Clinical Excellence (NICE) on the use of Bronchial Thermoplasty (BT) to treat...
-
Jan 23, 2012Johnson and Johnson's patents found invalid
Boston Scientific Corporation (NYSE: BSX) announces that the U.S. District Court for the District of New Jersey has found all the asserted patents in...
-
Jan 20, 2012
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and full year ended...
-
Jan 16, 2012Nine-month data presented at ISET support safety and efficacy of Epic Stent in iliac stenting
Boston Scientific Corporation (NYSE: BSX) reports nine-month clinical endpoint data from its ORION trial, demonstrating excellent outcomes...
-
Jan 4, 2012Boston Scientific's Alair® Bronchial Thermoplasty System Achieves Important Reimbursement MilestonesCMS pass-through payment and new CPT®[1] codes established for catheter-based procedure to treat severe asthma
Boston Scientific Corporation (NYSE: BSX) announced that the Centers for Medicare and Medicaid Services (CMS), the agency that administers the Medicare...
-
Jan 3, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco. Hank...
-
Dec 12, 2011
Boston Scientific Corporation (NYSE: BSX) announces the U.S. launch of its Charger™ PTA Balloon Catheter, a 0.035" percutaneous transluminal...
-
Dec 8, 2011World's first and only 16-contact percutaneous lead provides innovative, new option for physicians to treat chronic pain
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval of the Infinion™ 16 Percutaneous...
-
Nov 30, 2011Extended ICD/CRT-D program offers warranties up to 10 years
Boston Scientific Corporation (NYSE: BSX) announced that, along with today's introduction of a new family of INCEPTA™ and ENERGEN™ implantable...
-
Nov 30, 2011New family of cardiac devices offers excellent longevity and industry's longest warranty
Boston Scientific Corporation (NYSE: BSX) announces FDA approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy...
-
Nov 22, 2011Approval marks transition to internally manufactured everolimus-eluting stent in the U.S.
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting...
-
Nov 18, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray 23rd Annual Healthcare Conference on November 30 in New...
-
Nov 16, 2011Innovative left atrial appendage closure device offers proven alternative to anticoagulant drugs for patients in atrial fibrillation at high risk for stroke
Boston Scientific Corporation's (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA) Closure Device has been implanted in the first patients in Latin...
-
Nov 15, 2011
Boston Scientific Corporation (NYSE: BSX) commends the leadership of Senator Al Franken (D-MN), Senator Lamar Alexander (R-TN) and Senator John Kerry...
-
Nov 11, 2011Positive results from COBRA trial presented at TCT
Boston Scientific Corporation (NYSE: BSX) welcomed positive outcomes from the COBRA clinical trial, which evaluated post-dilation of...
-
Nov 11, 2011EVOLVE trial evaluates fourth-generation everolimus-eluting coronary stent with ultra-thin abluminal bioabsorbable polymer
Boston Scientific Corporation (NYSE: BSX) reports results from the EVOLVE First Human Use trial demonstrating the non-inferiority of...
-
Nov 8, 2011
Boston Scientific Corporation (NYSE: BSX) reports positive outcomes from the CABANA post-approval study of the Carotid WALLSTENT®...
-
Nov 8, 2011PLATINUM Long Lesion clinical results presented at TCT show no cardiac death, heart attack or stent thrombosis at one year
Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating excellent...
-
Nov 8, 2011Long-term results presented from two studies evaluating advanced paclitaxel-eluting stent
Boston Scientific Corporation (NYSE: BSX) reports positive long-term data from the PERSEUS clinical program, which demonstrated...
-
Nov 2, 2011Multi-center study published in Gastrointestinal Endoscopy is largest ever reported on peroral cholangioscopy
Boston Scientific Corporation (NYSE: BSX) welcomes study results published in the October issue of Gastrointestinal Endoscopy showing an overall...
-
Nov 1, 2011Clinical presentations to include 12-month data on fourth-generation SYNERGY™ Stent
Boston Scientific Corporation (NYSE: BSX) releases the schedule of its major events and product-related clinical research for the Cardiovascular...
-
Oct 27, 2011Video demonstration of CardioTeach™ app by Dr. Kenneth Stein available online
Boston Scientific Corporation (NYSE: BSX) introduces its CardioTeach™ iPad® app, an industry-first, free educational resource to help healthcare...
-
Oct 20, 2011
Boston Scientific Corporation (NYSE: BSX) announces financial results for the third quarter ended September 30, 2011, as well as updated sales and...
-
Oct 18, 2011
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in a clinical trial to evaluate its WallFlex® Biliary RX Fully Covered Stent for...